- Home
- BB vs TVTX Comparison
BB vs TVTX Comparison
Compare BB & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- TVTX
- Stock Information
- Founded
- BB 1984
- TVTX 2008
- Country
- BB Canada
- TVTX United States
- Employees
- BB N/A
- TVTX N/A
- Industry
- BB
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- BB
- TVTX Health Care
- Exchange
- BB Nasdaq
- TVTX Nasdaq
- Market Cap
- BB 1.5B
- TVTX 1.3B
- IPO Year
- BB 1997
- TVTX N/A
- Fundamental
- Price
- BB $2.32
- TVTX $18.26
- Analyst Decision
- BB Hold
- TVTX Buy
- Analyst Count
- BB 5
- TVTX 13
- Target Price
- BB $3.39
- TVTX $23.46
- AVG Volume (30 Days)
- BB 8.6M
- TVTX 1.4M
- Earning Date
- BB 12-18-2024
- TVTX 10-31-2024
- Dividend Yield
- BB N/A
- TVTX N/A
- EPS Growth
- BB N/A
- TVTX N/A
- EPS
- BB N/A
- TVTX N/A
- Revenue
- BB $637,000,000.00
- TVTX $203,447,000.00
- Revenue This Year
- BB N/A
- TVTX $62.45
- Revenue Next Year
- BB $7.65
- TVTX $59.30
- P/E Ratio
- BB N/A
- TVTX N/A
- Revenue Growth
- BB N/A
- TVTX 57.08
- 52 Week Low
- BB $2.01
- TVTX $5.12
- 52 Week High
- BB $4.44
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- BB 43.45
- TVTX 55.85
- Support Level
- BB $2.29
- TVTX $16.86
- Resistance Level
- BB $2.42
- TVTX $19.51
- Average True Range (ATR)
- BB 0.08
- TVTX 1.10
- MACD
- BB -0.00
- TVTX -0.19
- Stochastic Oscillator
- BB 25.81
- TVTX 40.35
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communication for enterprises. The firm provides endpoint management and protection to enterprises, specializing in regulated industries like government, as well as embedded software to the automotive, medical, and industrial markets.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.